Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

CDK1 protein offers clues to which breast cancers will resist targeted therapy (opens in a new tab)

medicalxpress.com · 2026-10-30

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of six claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 2 supported
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe study, published in Advanced Science, focused on estrogen receptor-positive (ER+) breast cancer and the CDK4/6 inhibitors commonly used with hormone therapy.View evidenceHide evidence

Why this verdict

The profile supports that the paper focuses on ER+ breast cancer and CDK4/6 inhibition/palbociclib response. However, the supplied abstract-depth profile does not verify the publication venue, Advanced Science, and only indirectly supports the phrasing about CDK4/6 inhibitors being commonly used with hormone therapy. The core scientific focus is supported, but the full claim as stated is not fully verifiable from the supplied profile.

1

Study evidence

pCDK1T161 was reported to be specifically upregulated in invasive ductal carcinoma (IDC) in the clinical cohort analyses.

“Clinically, we identified that pCDK1T161 is specifically upregulated in IDC, and that pCDK1Y15 is prognostic of poor relapse-free survival in stage 1 disease.”
2

Study evidence

CDK1/cyclin B1 complex abundance and CDK1 activity are transiently suppressed after CDK4/6 inhibition and then rebound within approximately three days.

“We further characterized CDK1 activity as part of a dynamic adaptive response to CDK4/6 inhibition: the CDK1/cyclin B1 complex was suppressed, then rebounded within 3 days.”
Claim 2 of 6Not coveredIn more than 400 patient biopsy samples, higher CDK1 activity was linked to more aggressive cancer and worse outcomes.View evidenceHide evidence

As statedmore than 400 patients

Why this verdict

The profile supports the general association between phosphorylated CDK1 markers and invasive/aggressive disease or poorer relapse-free survival: pCDK1T161 was upregulated in IDC and pCDK1Y15 was prognostic for poor relapse-free survival in stage 1 ER+ disease. However, the abstract-depth profile does not provide the story’s stated magnitude of more than 400 biopsy samples, nor does it verify the exact wording of 'higher CDK1 activity' across that sample set. The direction is supported, but the sample-size and measurement details are not verifiable at this depth.

1

Study evidence

pCDK1T161 was reported to be specifically upregulated in invasive ductal carcinoma (IDC) in the clinical cohort analyses.

“Clinically, we identified that pCDK1T161 is specifically upregulated in IDC, and that pCDK1Y15 is prognostic of poor relapse-free survival in stage 1 disease.”
Claim 3 of 6Not coveredIn tumors that did not respond to CDK4/6 inhibitors, CDK1 and related genes stayed switched on, and the same pattern was seen in advanced cancers that grew back despite treatment.View evidenceHide evidence

Why this verdict

The supplied profile supports related findings: NeoPalAna non-responders incompletely suppressed CDK1, palbociclib-resistant cells recovered basal CDK1, non-responsive mouse tumors had elevated Cdk1 activity, and CDK1 was elevated in CDK4/6 inhibitor-resistant patient tumors. However, the story’s gene-level wording that 'CDK1 and related genes stayed switched on' is not directly supported by the abstract-depth profile, which describes CDK1 activity, CDK1/cyclin B1 complex dynamics, and CDK1 elevation rather than specific gene-expression persistence. The advanced/resistant tumor pattern is directionally supported but not fully verifiable as phrased.

1

Study evidence

CDK1/cyclin B1 complex abundance and CDK1 activity are transiently suppressed after CDK4/6 inhibition and then rebound within approximately three days.

“We further characterized CDK1 activity as part of a dynamic adaptive response to CDK4/6 inhibition: the CDK1/cyclin B1 complex was suppressed, then rebounded within 3 days.”
2

Study evidence

In the NeoPalAna trial, non-responders incompletely suppressed CDK1 following palbociclib treatment.

“In the NeoPalAna trial, non-responders incompletely suppressed CDK1.”
Claim 4 of 6Not coveredThe team says the findings need to be tested in larger patient groups and could eventually open the door to drugs targeting CDK1.View evidenceHide evidence

Why this verdict

The profile supports that CDK1 is positioned as a candidate biomarker/resistance marker and that clinical utility has not been prospectively validated. But the supplied abstract-depth profile does not explicitly verify the story’s statement that the team said the findings need testing in larger patient groups, nor does it directly document a future-drug-development claim about CDK1-targeting drugs. The caveated, speculative framing is appropriate, but the specific forward-looking statements are not fully verifiable from the supplied profile.

1

Study evidence

CDK1/cyclin B1 complex abundance and CDK1 activity are transiently suppressed after CDK4/6 inhibition and then rebound within approximately three days.

“We further characterized CDK1 activity as part of a dynamic adaptive response to CDK4/6 inhibition: the CDK1/cyclin B1 complex was suppressed, then rebounded within 3 days.”
2

Study evidence

In the NeoPalAna trial, non-responders incompletely suppressed CDK1 following palbociclib treatment.

“In the NeoPalAna trial, non-responders incompletely suppressed CDK1.”
Claim 5 of 6SupportedResearchers at the Garvan Institute of Medical Research discovered that CDK1 activity in breast cancers is linked to how they respond to a common therapy, which could support more personalized treatment.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that CDK1 activity/dynamics are linked to CDK4/6 inhibitor response or resistance across trial specimens, mouse tumors, resistant cell models, and resistant patient tumors. The story frames this as a hedged, potential personalization use rather than a validated clinical test, which matches the candidate-biomarker framing. The Garvan affiliation itself is not evidenced in the supplied paper profile, but the scientific claim is supported.

1

Study evidence

CDK1/cyclin B1 complex abundance and CDK1 activity are transiently suppressed after CDK4/6 inhibition and then rebound within approximately three days.

“We further characterized CDK1 activity as part of a dynamic adaptive response to CDK4/6 inhibition: the CDK1/cyclin B1 complex was suppressed, then rebounded within 3 days.”
2

Study evidence

In the NeoPalAna trial, non-responders incompletely suppressed CDK1 following palbociclib treatment.

“In the NeoPalAna trial, non-responders incompletely suppressed CDK1.”
Claim 6 of 6SupportedA preclinical model with a fluorescent sensor showed CDK1 activity rose as tumors became invasive.View evidenceHide evidence

Why this verdict

Supported. The profile states that a novel MMTV-PyMT;MMTV-Cre;Cdk1-FRET biosensor mouse was used for in situ/real-time imaging and visualized Cdk1 upregulation during transition to invasive ductal carcinoma, which matches the story’s statement that CDK1 activity rose as tumors became invasive.

1

Study evidence

Cdk1 activity, measured by a Cdk1-FRET biosensor, is upregulated in situ during the transition to invasive ductal carcinoma in the MMTV-PyMT;MMTV-Cre biosensor mouse.

“integrate real-time imaging of a novel Cdk1 activity biosensor mouse”
Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

8 things the story did carry across
  • Novel Cdk1-FRET biosensor mouse showing in vivo Cdk1 upregulation during transition to invasive ductal carcinoma.
  • Clinical tissue findings that phosphorylated CDK1 epitopes are candidate ER+ breast cancer biomarkers: pCDK1T161 upregulated in IDC and pCDK1Y15 prognostic for poor relapse-free survival in stage 1 disease.
  • CDK1/cyclin B1 dynamics after CDK4/6 inhibition: suppression followed by rebound within about three days, interpreted as an adaptive response.
  • NeoPalAna trial correlative analysis showing non-responders incompletely suppressed CDK1 after palbociclib treatment.
  • In vitro palbociclib-resistant cell models recovered basal CDK1.
  • In vivo non-responsive mouse tumors exhibited elevated Cdk1 activity during CDK4/6 inhibitor response experiments.
  • CDK1 was elevated in CDK4/6 inhibitor-resistant patient tumors.
  • The clinical resistance and biomarker findings are correlative/candidate-biomarker evidence, not prospective validation of a clinical CDK1 test or proof of clinical utility.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

7

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalEstablish CDK1 activity as a dynamic in vivo marker of progression to invasive ductal carcinoma (IDC) using a novel Cdk1-FRET biosensor mouse.in vivo animal imagingExpand

In plain English

Using a novel MMTV-PyMT;MMTV-Cre;Cdk1-FRET biosensor transgenic mouse, the authors performed in situ real-time FRET imaging and observed upregulation of Cdk1 activity during the transition to invasive ductal carcinoma (IDC), supporting CDK1 as a dynamic in vivo marker of progression.

Key findings

  • Cdk1 activity, measured by a Cdk1-FRET biosensor, is upregulated in situ during the transition to invasive ductal carcinoma in the MMTV-PyMT;MMTV-Cre biosensor mouse.
“integrate real-time imaging of a novel Cdk1 activity biosensor mouse”
2secondary dataEstablish phosphorylated CDK1 epitopes (pCDK1T161, pCDK1Y15) as clinically relevant biomarkers in ER+ breast cancer (IDC association; prognosis in early-stage disease).observational cohort studyExpand

In plain English

The paper reports clinical cohort analyses identifying two phosphorylated CDK1 epitopes as candidate biomarkers in ER+ breast cancer: pCDK1T161 is described as specifically upregulated in invasive ductal carcinoma (IDC), and pCDK1Y15 is reported as prognostic for poorer relapse-free survival in stage 1 disease. These observations are presented as part of clinical tissue analyses and survival/prognostic assessment.

Key findings

  • pCDK1T161 was reported to be specifically upregulated in invasive ductal carcinoma (IDC) in the clinical cohort analyses.
  • pCDK1Y15 was reported as prognostic of poor relapse‑free survival in stage 1 ER+ breast cancer.
“Clinically, we identified that pCDK1T161 is specifically upregulated in IDC, and that pCDK1Y15 is prognostic of poor relapse-free survival in stage 1 disease.”
What this piece can’t prove
  • Summary is based solely on abstract statements; full cohort characteristics, measurement methods, and statistical results are not available here.
  • Unclear whether prognostic analyses accounted for clinical covariates or multiple testing.

1 further detail could not be confirmed from the summary.

3in vitroDefine CDK1 dynamics as an adaptive response and resistance marker to CDK4/6 inhibition across clinical trial samples, patient tumors, mouse tumors, and in-vitro models.CDK4/6 inhibitor time-course with protein/activity readoutsExpand

In plain English

Following CDK4/6 inhibition, the CDK1/cyclin B1 complex and CDK1 activity undergo a transient suppression followed by a rebound within ~3 days, a dynamic interpreted as an adaptive response; incomplete suppression or recovery of CDK1 is associated with lack of response or resistance across in‑vitro models, mouse tumors, and clinical samples.

Key findings

  • CDK1/cyclin B1 complex abundance and CDK1 activity are transiently suppressed after CDK4/6 inhibition and then rebound within approximately three days.
  • Incomplete suppression or recovery of CDK1 associates with non-response or resistance to CDK4/6 inhibition in multiple systems (clinical trial non-responders, palbociclib-resistant cell lines, non-responsive mouse tumors, and resistant patient tumors).
“We further characterized CDK1 activity as part of a dynamic adaptive response to CDK4/6 inhibition: the CDK1/cyclin B1 complex was suppressed, then rebounded within 3 days.”
What this piece can’t prove
  • Timing is reported as 'within 3 days' but precise temporal resolution, variability, and whether rebound persists beyond the stated window are not specified.

2 further details could not be confirmed from the summary.

4human in vivoDefine CDK1 dynamics as an adaptive response and resistance marker to CDK4/6 inhibition across clinical trial samples, patient tumors, mouse tumors, and in-vitro models.Interventional clinical trial (neoadjuvant palbociclib) correlative biomarker analysisExpand

In plain English

In NeoPalAna trial correlative analyses, tumors from patients who did not respond to neoadjuvant palbociclib showed incomplete suppression of CDK1 compared with responders, supporting CDK1 dynamics as a candidate adaptive response and resistance biomarker to CDK4/6 inhibition.

Key findings

  • In the NeoPalAna trial, non-responders incompletely suppressed CDK1 following palbociclib treatment.
  • Therefore, CDK1 dynamics (suppression vs incomplete suppression) are presented as a candidate adaptive response/resistance marker to CDK4/6 inhibition in trial specimens.
“In the NeoPalAna trial, non-responders incompletely suppressed CDK1.”
What this piece can’t prove
  • Findings reported are correlative from trial specimens; the abstract does not provide evidence of prospective validation or clinical utility.

2 further details could not be confirmed from the summary.

5in vitroDefine CDK1 dynamics as an adaptive response and resistance marker to CDK4/6 inhibition across clinical trial samples, patient tumors, mouse tumors, and in-vitro models.In vitro palbociclib-resistant cell modelExpand

In plain English

In in vitro palbociclib-resistant cell models, basal CDK1 was recovered compared with pre-resistance conditions, indicating CDK1 re-emergence as part of an adaptive/resistance phenotype to CDK4/6 inhibition.

Key findings

  • Palbociclib-resistant cells recovered basal CDK1 in vitro (abstract statement).
“Palbociclib-resistant cells recovered basal CDK1 in vitro”
What this piece can’t prove
  • Unclear which specific assays and endpoints were used to define CDK1 recovery without access to the full text.

1 further detail could not be confirmed from the summary.

6in vivo animalDefine CDK1 dynamics as an adaptive response and resistance marker to CDK4/6 inhibition across clinical trial samples, patient tumors, mouse tumors, and in-vitro models.in vivo treatment response mouseExpand

In plain English

In a Cdk1-FRET biosensor mouse model subjected to in vivo CDK4/6 inhibitor treatment, tumors classified as non-responsive exhibited elevated Cdk1 activity measured in vivo, consistent with CDK1 upregulation as part of an adaptive response or resistance phenotype.

Key findings

  • In the biosensor mouse model, tumors classified as non-responsive to CDK4/6 inhibition exhibited elevated Cdk1 activity measured in vivo.
“non-responsive tumors exhibited elevated Cdk1 activity in vivo”
What this piece can’t prove
  • Summary is based on abstract-only information; primary manuscript text, figures, and methods are not available here for verification.
  • No quantitative metrics, statistical analyses, or sample sizes reported in abstract for the in vivo non-response observation.
  • Abstract does not specify which CDK4/6 inhibitor was used in the mouse experiments or detailed timing of activity measurements.
7secondary dataDefine CDK1 dynamics as an adaptive response and resistance marker to CDK4/6 inhibition across clinical trial samples, patient tumors, mouse tumors, and in-vitro models.Observational comparative analysis of post-treatment/progression tumor biopsies by resistance statusExpand

In plain English

The paper reports that CDK1 is elevated in patient tumors classified as CDK4/6 inhibitor–resistant, based on analysis of clinical tumor specimens. This observation is presented as part of evidence positioning CDK1 as an indicator of adaptive responses and resistance to CDK4/6 inhibition in human tumors.

Key findings

  • CDK1 was elevated in CDK4/6 inhibitor–resistant patient tumors.
“CDK1 was elevated in CDK4/6 inhibitor-resistant patient tumors.”
What this piece can’t prove
  • Assay platform and whether measurements reflect total CDK1 protein, specific phosphorylation sites, or activity readouts are unspecified.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

SelectedOpen access

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer

Advanced Science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Author Index

2026 2Nd International Conference on IOT, Data Science and Advanced Computing (IDSAC) · 2026 · Crossref

Source (opens in a new tab)
Candidate

Next Generation S/TEM Platforms for Semiconductor Pathfinding: An Integrated Multi-Modal and Multi-Dimensional Approach for Advanced Logic and Memory Devices

Microscopy and Microanalysis · 2026 · Crossref

Source (opens in a new tab)
Candidate

Environmental Strategy and Performance in Shipping

The Handbook of Maritime Economics and Business · 2026 · Crossref

Source (opens in a new tab)

And 31 more candidates considered.